ADC Therapeutics SARL   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Epalinges Switzerland (2012)

Organization Overview

First Clinical Trial
2015
NCT02432235
First Marketed Drug
2021
loncastuximab
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ADC Therapeutics SA | ADC Therapeutics S.A.